SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 SPARC acquires Bioprojet’s right s for SCD -044

FOR IMMEDIATE RELEASE SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 SPARC acquires Bioprojet’s right s for SCD -044 MUMBAI – December 19, 2019, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that it has entered into an agreement with Biop rojet SCR (Bioprojet) to exclusively acquire Bioprojet’s rights to the investigational medic inal product SCD- 044. SPARC and Bioprojet co -owned all SCD- 044 related IP, developed through a research collaboration targeting Sphingosine-1-Phosphate Receptors (S1PR) to treat various autoimmune disorders. The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044. “This is an important deal for us. SPARC has been working on SCD-044 in collaboration with Bioprojet. This acquisition will provide us with expanded freedom to operate and an opportunity to build on promising data from early stage clinical trials, " said Anil Raghavan, CEO of SPARC. “This agreement is further evidence of SPARC's commitment to see k out novel treatments to address important unmet medical conditions”. Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044. About SCD-044: SCD-044 is a novel investigational oral, selective S1P1 receptor agonist under development for the treatment of autoimmune diseases. Phase I studies for SCD-044 have been completed. About SPARC (CIN: L73100GJ2006PLC047837): Sun Pharma A dvanced Research Company Ltd. ( SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life. About Bioprojet: Boprojet SCR is a research -based pharmaceutical company . Bioprojet is headquartered in Paris, France and its Research Center located in Rennes, France. Its activity is focused on the design, synthesis and development of novel classes of drugs for unmet medical needs. For more information visit www.bioprojet.com. Disclaimer: Statements in this document describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. Media Contacts: Jaydeep Issrani Tel +91 22 66455645, Extn: 5787 Tel Direct +91 22 6645 5787 Mobile +91-9820216916 E mail [email protected]

The release as fetched from its publisher. sparc.life ↗